Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.

Endocrine-related cancer - 1 Jun 2012

Chen Hongbing, Sun Yin, Wu Chengyu, Magyar Clara E, Li Xinmin, Cheng Liang, Yao Jorge L, Shen Steven, Osunkoya Adeboye O, Liang Chaozhao, Huang Jiaoti

Abstract excerpt

Small cell neuroendocrine carcinoma (SCNC) of the prostate is a variant form of prostate cancer that occurs de novo or as a recurrent tumor in patients who received hormonal therapy for prostatic adenocarcinoma. It is composed of pure neuroendocrine (NE) tumor cells, but unlike the scattered NE cells in benign prostate and adenocarcinoma that are quiescent, the NE cells in SCNC are highly proliferative and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Small Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Interleukin-8

Share to Prostatic Neoplasms

Share to Receptors, Interleukin-8B

Share to Signal Transduction

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 22389383
DOI: 10.1530/ERC-11-0368
PMCID: PMC3433057

Genes

CXCR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.PMID 22389383Read ↗

p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.Semantic proximity Read ↗

Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.Semantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

Clinicopathological and Genetic Analyses of Small Cell Neuroendocrine Carcinoma of the Prostate: Histological Features for Accurate Diagnosis and Toward Future Novel Therapies Short Running Title: Characteristics of Prostatic Small Cell Neuroendocrine CarcinomaSemantic proximity Read ↗

Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factorsSemantic proximity Read ↗

Role of MicroRNAs in Neuroendocrine Prostate CancerSemantic proximity Read ↗

[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].Semantic proximity Read ↗

Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinomaSemantic proximity Read ↗

Therapy considerations in neuroendocrine prostate cancer: what next?Semantic proximity Read ↗

Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.Semantic proximity Read ↗

Nuclear iASPP may facilitate prostate cancer progression.Semantic proximity Read ↗

CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.